trending Market Intelligence /marketintelligence/en/news-insights/trending/4-e-zlcCjS9YqnPKshWMMw2 content esgSubNav
In This List

Ovid secures fast track designation for nervous system disorder treatment

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Ovid secures fast track designation for nervous system disorder treatment

Ovid Therapeutics Inc. secured the U.S. Food and Drug Administration's fast track designation for its OV101 treatment for a nervous system disorder known as Angelman syndrome.

Angelman syndrome is a genetic disorder characterized by a variety of signs and symptoms. Characteristic features of this disorder include delayed development, intellectual disability, severe speech impairment, problems with movement and balance, seizures, sleep disorders and anxiety.

The company recently released positive data from its phase 1 trial and expanded the phase 2 stars study to include both adults and adolescents. Ovid expects results of the phase 2 trial in the second half of 2018.

OV101 also secured orphan drug designation for the treatment of Fragile X syndrome.